Article Abstract

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?

Authors: Brittney Chau, Ashwin Shinde, Arya Amini


The oncologic importance of an epidermal growth factor receptor (EGFR) mutation in the era of tyrosine-kinase inhibitors (TKIs) for patients with metastatic non-small cell lung cancer (NSCLC) cannot be overstated. The multiple positive trials evaluating gefitinib, erlotinib, and more recently osimeritinib as first line treatment of EGFR mutated NSCLC have revolutionized NSCLC management, with significantly improved oncologic and toxicity outcomes in this subset of patients (1-3).